Questions Roll In As UDI Expands In US; Debate Over System Adoption Continues
This article was originally published in SRA
While the US Food and Drug Administration's requirements relating to unique device identification (UDI) first took effect in 2014, the UDI mandate remains a dynamic issue for the medtech industry as more and more devices become subject to UDI labeling and database submissions each year.
You may also be interested in...
Japanese big pharma Eisai taps Celgene and Sanofi execs as its new VPs for corporate affairs and market access. And Freeline Therapeutics, developer of gene therapies for bleeding disorders, selects a former Alnylam Pharma SVP as CEO.
After two Indian vaccine makers, Serum Institute of India and Cadila Healthcare joined the fight against COVID-19, Bharat Biotech may follow suit. Others like Hilleman have decided against it for the moment while Panacea Biotech is weighing the pros and cons of developing a SARS-CoV-2 vaccine after a sour experience with H1N1.